vs
ANI PHARMACEUTICALS INC（ANIP）与PREFORMED LINE PRODUCTS CO（PLPC）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是PREFORMED LINE PRODUCTS CO的1.4倍（$247.1M vs $173.1M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 4.9%，领先6.3%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 3.6%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $11.8M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 10.8%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
ANIP vs PLPC — 直观对比
营收规模更大
ANIP
是对方的1.4倍
$173.1M
营收增速更快
ANIP
高出26.1%
3.6%
净利率更高
ANIP
高出6.3%
4.9%
自由现金流更多
ANIP
多$17.3M
$11.8M
两年增速更快
ANIP
近两年复合增速
10.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $173.1M |
| 净利润 | $27.5M | $8.4M |
| 毛利率 | — | 29.8% |
| 营业利润率 | 14.1% | 6.8% |
| 净利率 | 11.1% | 4.9% |
| 营收同比 | 29.6% | 3.6% |
| 净利润同比 | 367.5% | -19.3% |
| 每股收益（稀释后） | $1.14 | $1.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPPLPC
| Q4 25 | $247.1M | $173.1M | ||
| Q3 25 | $227.8M | $178.1M | ||
| Q2 25 | $211.4M | $169.6M | ||
| Q1 25 | $197.1M | $148.5M | ||
| Q4 24 | $190.6M | $167.1M | ||
| Q3 24 | $148.3M | $147.0M | ||
| Q2 24 | $138.0M | $138.7M | ||
| Q1 24 | $137.4M | $140.9M |
净利润ANIPPLPC
| Q4 25 | $27.5M | $8.4M | ||
| Q3 25 | $26.6M | $2.6M | ||
| Q2 25 | $8.5M | $12.7M | ||
| Q1 25 | $15.7M | $11.5M | ||
| Q4 24 | $-10.3M | $10.5M | ||
| Q3 24 | $-24.2M | $7.7M | ||
| Q2 24 | $-2.3M | $9.4M | ||
| Q1 24 | $18.2M | $9.6M |
毛利率ANIPPLPC
| Q4 25 | — | 29.8% | ||
| Q3 25 | — | 29.7% | ||
| Q2 25 | — | 32.7% | ||
| Q1 25 | — | 32.8% | ||
| Q4 24 | — | 33.3% | ||
| Q3 24 | — | 31.1% | ||
| Q2 24 | — | 31.9% | ||
| Q1 24 | — | 31.3% |
营业利润率ANIPPLPC
| Q4 25 | 14.1% | 6.8% | ||
| Q3 25 | 15.9% | 7.4% | ||
| Q2 25 | 6.6% | 10.1% | ||
| Q1 25 | 13.3% | 8.8% | ||
| Q4 24 | -2.3% | 10.5% | ||
| Q3 24 | -13.8% | 7.1% | ||
| Q2 24 | 3.7% | 8.1% | ||
| Q1 24 | 14.8% | 8.2% |
净利率ANIPPLPC
| Q4 25 | 11.1% | 4.9% | ||
| Q3 25 | 11.7% | 1.5% | ||
| Q2 25 | 4.0% | 7.5% | ||
| Q1 25 | 8.0% | 7.8% | ||
| Q4 24 | -5.4% | 6.3% | ||
| Q3 24 | -16.3% | 5.2% | ||
| Q2 24 | -1.7% | 6.8% | ||
| Q1 24 | 13.2% | 6.8% |
每股收益（稀释后）ANIPPLPC
| Q4 25 | $1.14 | $1.72 | ||
| Q3 25 | $1.13 | $0.53 | ||
| Q2 25 | $0.36 | $2.56 | ||
| Q1 25 | $0.69 | $2.33 | ||
| Q4 24 | $-0.45 | $2.13 | ||
| Q3 24 | $-1.27 | $1.54 | ||
| Q2 24 | $-0.14 | $1.89 | ||
| Q1 24 | $0.82 | $1.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | — |
| 总债务越低越好 | — | $38.3M |
| 股东权益账面价值 | $540.7M | $475.5M |
| 总资产 | $1.4B | $653.6M |
| 负债/权益比越低杠杆越低 | — | 0.08× |
8季度趋势，按日历期对齐
现金及短期投资ANIPPLPC
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — | ||
| Q1 24 | $228.6M | — |
总债务ANIPPLPC
| Q4 25 | — | $38.3M | ||
| Q3 25 | — | $36.0M | ||
| Q2 25 | — | $31.8M | ||
| Q1 25 | — | $29.1M | ||
| Q4 24 | — | $20.8M | ||
| Q3 24 | — | $27.2M | ||
| Q2 24 | — | $31.6M | ||
| Q1 24 | — | $55.0M |
股东权益ANIPPLPC
| Q4 25 | $540.7M | $475.5M | ||
| Q3 25 | $505.8M | $466.3M | ||
| Q2 25 | $436.8M | $460.7M | ||
| Q1 25 | $418.6M | $435.8M | ||
| Q4 24 | $403.7M | $422.3M | ||
| Q3 24 | $405.9M | $429.0M | ||
| Q2 24 | $455.8M | $416.2M | ||
| Q1 24 | $452.0M | $413.4M |
总资产ANIPPLPC
| Q4 25 | $1.4B | $653.6M | ||
| Q3 25 | $1.4B | $644.6M | ||
| Q2 25 | $1.3B | $631.5M | ||
| Q1 25 | $1.3B | $592.5M | ||
| Q4 24 | $1.3B | $573.9M | ||
| Q3 24 | $1.3B | $592.0M | ||
| Q2 24 | $920.8M | $572.6M | ||
| Q1 24 | $914.5M | $586.1M |
负债/权益比ANIPPLPC
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.08× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | — | 0.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $21.9M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $11.8M |
| 自由现金流率自由现金流/营收 | 11.8% | 6.8% |
| 资本支出强度资本支出/营收 | 0.5% | 5.9% |
| 现金转化率经营现金流/净利润 | 1.10× | 2.60× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $33.3M |
8季度趋势，按日历期对齐
经营现金流ANIPPLPC
| Q4 25 | $30.4M | $21.9M | ||
| Q3 25 | $44.1M | $18.9M | ||
| Q2 25 | $75.8M | $26.9M | ||
| Q1 25 | $35.0M | $5.7M | ||
| Q4 24 | $15.9M | $24.1M | ||
| Q3 24 | $12.5M | $9.4M | ||
| Q2 24 | $17.4M | $28.3M | ||
| Q1 24 | $18.3M | $5.8M |
自由现金流ANIPPLPC
| Q4 25 | $29.1M | $11.8M | ||
| Q3 25 | $38.0M | $8.3M | ||
| Q2 25 | $71.8M | $18.6M | ||
| Q1 25 | $32.5M | $-5.3M | ||
| Q4 24 | $13.5M | $20.6M | ||
| Q3 24 | $7.7M | $5.8M | ||
| Q2 24 | $13.0M | $24.6M | ||
| Q1 24 | $13.7M | $1.8M |
自由现金流率ANIPPLPC
| Q4 25 | 11.8% | 6.8% | ||
| Q3 25 | 16.7% | 4.7% | ||
| Q2 25 | 34.0% | 10.9% | ||
| Q1 25 | 16.5% | -3.6% | ||
| Q4 24 | 7.1% | 12.3% | ||
| Q3 24 | 5.2% | 3.9% | ||
| Q2 24 | 9.4% | 17.7% | ||
| Q1 24 | 10.0% | 1.3% |
资本支出强度ANIPPLPC
| Q4 25 | 0.5% | 5.9% | ||
| Q3 25 | 2.7% | 6.0% | ||
| Q2 25 | 1.9% | 4.9% | ||
| Q1 25 | 1.3% | 7.4% | ||
| Q4 24 | 1.3% | 2.1% | ||
| Q3 24 | 3.2% | 2.4% | ||
| Q2 24 | 3.2% | 2.7% | ||
| Q1 24 | 3.3% | 2.8% |
现金转化率ANIPPLPC
| Q4 25 | 1.10× | 2.60× | ||
| Q3 25 | 1.66× | 7.21× | ||
| Q2 25 | 8.87× | 2.12× | ||
| Q1 25 | 2.23× | 0.49× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 3.02× | ||
| Q1 24 | 1.00× | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PLPC
暂无分部数据
